Needham raised its price target on The Oncology Institute to $7 from $5 while maintaining a Buy rating on June 17, following BTIG's increase to $8 from $7 with a Buy rating on June 8. The Oncology Institute provides community-based oncology care through clinics and affiliated locations across several U.S. states. The recent analyst target increases suggest confidence in the platform's growth outlook as it scales value-based cancer care while narrowing losses and improving cash generation. Analysts see roughly 46.8% upside for the stock, which ranks first by average analyst upside in a screen of medical care facilities stocks.
The Oncology Institute, Inc.Needham and BTIG raised price targets and maintained Buy ratings, indicating analyst confidence in growth outlook.